Gilead Sciences, Inc. (GILD) operating KPIs
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.68+5.07 (+3.06%)
Close on Oct 30, 2026Market cap $211.64BP/E –Yield 1.85%
Gilead Sciences yescarta (axicabtagene ciloleucel) intangible asset — Net carrying value ($M) ($M)
Form 10-Q / 10-K Note 9 Goodwill and Intangible Assets
Latest, Q2 2026
3,780
Period ended Jun 30, 2026
Change on a year earlier
-9.7%
4,186 in Q2 2025
History
36 quarters
Since Q4 2016
Sources
32
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Yescarta (axicabtagene ciloleucel) intangible asset — Net carrying value ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 3,780 | -9.7% | Form 10-Q (filed 2026-08-06) ↗ |
| Q1 2026 | Mar 31, 2026 | 3,881 | -9.5% | Form 10-Q (filed 2026-05-07) ↗ |
| Q4 2025 | Dec 31, 2025 | 3,983 | -9.3% | Form 10-Q (filed 2026-08-06) ↗ |
| Q3 2025 | Sep 30, 2025 | 4,084 | -9.1% | Form 10-Q (filed 2025-11-07) ↗ |
| Q2 2025 | Jun 30, 2025 | 4,186 | -8.9% | Form 10-Q (filed 2025-08-07) ↗ |
| Q1 2025 | Mar 31, 2025 | 4,288 | -8.6% | Form 10-Q (filed 2025-05-07) ↗ |
| Q4 2024 | Dec 31, 2024 | 4,389 | -8.5% | Form 10-K (filed 2026-02-24) ↗ |
| Q3 2024 | Sep 30, 2024 | 4,491 | -8.3% | Form 10-Q (filed 2024-11-12) ↗ |
| Q2 2024 | Jun 30, 2024 | 4,593 | -8.1% | Form 10-Q (filed 2024-08-08) ↗ |
| Q1 2024 | Mar 31, 2024 | 4,694 | -8.0% | Form 10-Q (filed 2024-05-08) ↗ |
| Q4 2023 | Dec 31, 2023 | 4,796 | -7.8% | Form 10-K (filed 2025-02-28) ↗ |
| Q3 2023 | Sep 30, 2023 | 4,897 | -7.7% | Form 10-Q (filed 2023-11-07) ↗ |
| Q2 2023 | Jun 30, 2023 | 4,999 | -7.5% | Form 10-Q (filed 2023-08-04) ↗ |
| Q1 2023 | Mar 31, 2023 | 5,101 | -7.4% | Form 10-Q (filed 2023-05-03) ↗ |
| Q4 2022 | Dec 31, 2022 | 5,202 | -7.3% | Form 10-K (filed 2024-02-23) ↗ |
| Q3 2022 | Sep 30, 2022 | 5,304 | -7.1% | Form 10-Q (filed 2022-11-02) ↗ |
| Q2 2022 | Jun 30, 2022 | 5,406 | -7.0% | Form 10-Q (filed 2022-08-08) ↗ |
| Q1 2022 | Mar 31, 2022 | 5,507 | -6.9% | Form 10-Q (filed 2022-05-04) ↗ |
| Q4 2021 | Dec 31, 2021 | 5,609 | +10.1% | Form 10-K (filed 2023-02-22) ↗ |
| Q3 2021 | Sep 30, 2021 | 5,710 | +10.2% | Form 10-Q (filed 2021-11-03) ↗ |
| Q2 2021 | Jun 30, 2021 | 5,812 | +10.3% | Form 10-Q (filed 2021-08-05) ↗ |
| Q1 2021 | Mar 31, 2021 | 5,914 | +10.5% | Form 10-Q (filed 2021-05-06) ↗ |
| Q4 2020 | Dec 31, 2020 | 5,095 | -6.3% | Form 10-Q (filed 2021-11-03) ↗ |
| Q3 2020 | Sep 30, 2020 | 5,181 | -6.2% | Form 10-Q (filed 2020-11-04) ↗ |
| Q2 2020 | Jun 30, 2020 | 5,267 | -6.1% | Form 10-Q (filed 2020-08-06) ↗ |
| Q1 2020 | Mar 31, 2020 | 5,353 | -6.1% | Form 10-Q (filed 2020-05-06) ↗ |
| Q4 2019 | Dec 31, 2019 | 5,439 | -6.0% | Form 10-Q (filed 2020-05-06) ↗ |
| Q3 2019 | Sep 30, 2019 | 5,525 | -5.9% | Form 10-Q (filed 2019-11-05) ↗ |
| Q2 2019 | Jun 30, 2019 | 5,612 | -5.8% | Form 10-Q (filed 2019-08-06) ↗ |
| Q1 2019 | Mar 31, 2019 | 5,698 | -5.7% | Form 10-Q (filed 2019-05-08) ↗ |
| Q4 2018 | Dec 31, 2018 | 5,784 | -5.6% | Form 10-Q (filed 2019-11-05) ↗ |
| Q3 2018 | Sep 30, 2018 | 5,870 | – | Form 10-Q (filed 2018-11-06) ↗ |
| Q2 2018 | Jun 30, 2018 | 5,956 | – | Form 10-Q (filed 2018-08-06) ↗ |
| Q1 2018 | Mar 31, 2018 | 6,042 | – | Form 10-Q (filed 2018-05-09) ↗ |
| Q4 2017 | Dec 31, 2017 | 6,128 | – | Form 10-K (filed 2019-02-26) ↗ |
| Q4 2016 | Dec 31, 2016 | 0 | – | Form 10-K (filed 2018-02-27) ↗ |
Breakdown
What makes up yescarta (axicabtagene ciloleucel) intangible asset — net carrying value ($m)
Cite this data
StockData. (2026). Gilead Sciences Yescarta (axicabtagene ciloleucel) intangible asset — Net carrying value ($M) ($M), quarterly Q4 2016–Q2 2026 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/intang_yescarta_net
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.